Patients with delayed platelet recovery post-PBPC transplant (PBPCT) are a high-risk group for thrombocytopenic bleeding and platelet transfusion dependence. Total CD34
Thrombocytopenic bleeding and prolonged dependence on platelet transfusions are associated with decreased survival after both autologous and allogeneic transplants despite the use of mobilized peripheral blood progenitor cells (PBPCs) to facilitate rapid hematopoietic recovery.
1 Platelet transfusions protect patients from serious bleeding but at significant expense and risk of transmission of infections, allergic complications, and refractoriness due to alloimmunization. 2, 3 Risk factors associated with delayed platelet recovery post-autotransplant include a diagnosis of acute myeloid leukemia, 1, 4 infection prior to engraftment, 1 CMV positivity, 1 melphalan-containing myeloablative chemotherapy regimens, 5 and the use of BM instead of PBPCs. [6] [7] [8] [9] The more rapid engraftment with PBPCs has been attributed to an overall increase in the number of CD34 + cells reinfused. 10 The total CD34 + cell dosage has been proposed as the most significant predictor of engraftment kinetics, with rapid platelet recovery being achieved at 5.0 × 10 6 /kg or greater. [11] [12] [13] [14] Nevertheless, a considerable percentage of patients who receive these large numbers of CD34 + PBPCs still experience delayed platelet recovery and require supportive platelet transfusions. 15 Failure to achieve rapid platelet recovery in these patients may be due to poor mobilization of Mk progenitors. Characterization of CD34 + cell populations by flow cytometry has shown that the number of reinfused Mk progenitors (CD41 + , CD42 + , CD61 + ) may be a significant factor in determining post-PBPCT platelet recovery. [16] [17] [18] [19] A measure of Mk progenitor cell mass prior to mobilization may therefore allow the early identification of patients with a diminished ability to mobilize Mk progenitors.
TPO, the Mpl ligand responsible for Mk proliferation and maturation, has recently been purified and cloned. [20] [21] [22] [23] The Mpl receptor has been identified on platelets, megakaryo-cytes, and late progenitors of the Mk lineage. 24 It has therefore been proposed that serum TPO levels are reflective of total Mk mass. [24] [25] [26] [27] [28] With the recent development of sensitive ELISAs, [28] [29] [30] changes in endogenous TPO levels may be used as an indicator of the Mk reserve of patients undergoing PBPCT.
Late Mk precursors such as CD34 + /CD41 + cells have been shown to be acutely responsive to changes in the level of TPO. 24, 31, 32 Therefore, an alternative explanation for delayed platelet engraftment in PBPCT patients is a deficiency of endogenous TPO post-transplant. Recombinant forms of Mpl ligand (r-ML) may be of clinical benefit if endogenous TPO concentrations are inadequate for the reconstitution of megakaryocytopoiesis.
In the present study, a minimum of 10 × 10 6 CD34
+ cells/kg were reinfused in patients receiving myeloablative chemotherapy for various malignancies. The objective was to achieve the shortest time to platelet engraftment by reinfusing twice the recommended dose of CD34 + PBPCs.
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The proportion of patients not achieving this time was identified and compared to those achieving rapid recovery. Pretreatment and treatment variables including the dose of CD34 + Mk progenitors reinfused were studied. Changes in endogenous TPO levels during mobilization were analyzed to determine whether they were predictive of CD34 + cell and subset yields (including Mk progenitors). Moreover, to determine whether circulating TPO was deficient in patients with delayed platelet recovery, serial levels of endogenous TPO were monitored.
Materials and methods

Patients
Thirty consecutive patients with chemosensitive malignancies were entered on protocols for PBPC mobilization and myeloablative chemotherapy followed by PBPCT. There were 20 females and 10 males with a median age of 48 (range: 23-66) years.
Diagnoses included breast cancer (n = 17), acute myeloid leukemia (AML; n = 1), chronic myelogenous leukemia (CML; n = 1), non-Hodgkin's lymphoma (NHL; n = 2), Hodgkin's disease (HD; n = 1), multiple myeloma (MM; n = 2), ovarian cancer (n = 3), and germ cell tumor (n = 3). Marrow disease and cellularity were assessed by histologic examination of marrow biopsies. Patients were eligible for PBPC collection if marrow biopsies prior to harvest showed no evidence of disease.
All patients had Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and no evidence of active infection, adequate cardiac function (left ventricular ejection fraction Ͼ50%), pulmonary function (forced expiratory volume in 1 s Ͼ75%), renal function (serum creatinine Ͻ2.0 mg/dl), hepatic function (bilirubin Ͻ2.0 mg/dl) and normal bone marrow function (WBC Ͼ3.5 × 10 9 /l, platelet count Ͼ100 × 10 9 /l). Written informed consent was obtained from all patients and protocols were approved by the Ethical and Scientific Review Committee of the Bone Marrow/Stem Cell Transplant Institute at Florida Medical Center, Fort Lauderdale, FL, USA.
Mobilization, collection and cryopreservation of PBPCs
Hematopoietic progenitor cells were mobilized by chemotherapy treatment followed by 5 g/kg/day s.c. G-CSF (Filgrastim, Amgen, Thousand Oaks, CA, USA) until the completion of leukapheresis. In the patient with AML, the mobilizing regimen consisted of idarubicin 12 mg/m 2 once daily i.v. for 3 consecutive days (total dose 36 mg/m 2 ) and high-dose Ara-C 3000 mg/m 2 twice daily i.v. for 6 consecutive days (total 12 doses) followed by G-CSF from day 7. In the patient with CML, the mobilizing regimen was idarubicin 10 mg/m 2 once daily i.v. for 4 consecutive days (total dose 40 mg/m 2 ), and ara-C 1000 mg/m 2 once daily i.v. for 5 consecutive days (total dose 5000 mg/m 2 ) and etoposide 150 mg/m 2 once daily i.v. for 3 consecutive days (total dose 450 mg/m 2 ) followed by G-CSF from day 6. In patients with all other diagnoses, PBPCs were mobilized with CY 1500 mg/m 2 once daily i.v. for 3 consecutive days (total dose 4500 mg/m 2 ) and etoposide 200 mg/m 2 once daily i.v. for 3 consecutive days (total dose 600 mg/m 2 ) followed by G-CSF from day 4.
Leukapheresis was started when the WBC exceeded 3.0 × 10 9 /l and an unequivocal increase in the peripheral blood CD34
+ percentage was observed. Large volume leukaphereses were performed daily with 20 to 30 l of blood processed at a rate of 70 to 110 ml/min using a continuousflow blood cell separator (COBE BCT, Lakewood, CO, USA). Daily leukapheresis was continued until a target number of 1 × 10 7 CD34 + cells per kg of body weight were collected. If after five procedures 50% or more of the target number of cells was not achieved the patients were reevaluated to determine whether they would continue on the study protocol. One patient with stage II breast cancer did not achieve the PBPC harvest target number of cells. In this patient, autologous bone marrow was harvested in addition to PBPCs.
The leukapheresis product was mixed with DMSO (Cryoserv, Research Industries, Salt Lake City, UT, USA) to a final concentration of 10% of the total volume. The final suspension was transferred into freezing bags and frozen at a controlled rate to −100°C in a Kryo10 (Planer Products, Middlesex, UK). The frozen cells were then transferred into liquid nitrogen and stored at −196°C.
High-dose chemotherapy and PBPCT
Patients received one of several myeloablative regimens that were disease-specific. On days Forty-eight hours after the last dose of chemotherapy (day 0) the cryopreserved leukapheresis products were thawed rapidly at the bedside and reinfused via an indwelling double-lumen right atrial catheter. All patients received 5 g/kg/day s.c. G-CSF starting on day 0 after PBPC infusion and continued until the WBC in the peripheral blood exceeded 5.0 × 10 9 /l. Three patients with breast cancer received additional GM-CSF (Sargramostim; Immunex, Seattle, WA, USA) 250 g/m 2 daily by s.c. injection due to a slow neutrophil recovery post-transplant (ANC Ͻ0.5 × 10 9 /l on day +10). Irradiated RBC transfusions were given for hematocrit levels less than 24% and irradiated platelet transfusions for platelet counts less than 20 × 10 9 /l. Post-transplant neutrophil recovery was defined as the first of 2 consecutive days following the nadir on which the patient's ANC was greater than 0.5 × 10 9 /l. Early platelet recovery was defined as the first of 7 consecutive days on which the patient's unsupported platelet count was greater than 20 × 10 9 /l. Stable platelet recovery was defined as the number of days to platelet recovery of 50 × 10 9 /l with no subsequent decrease in peripheral blood platelet counts.
Collection of serum samples for TPO
Blood samples (serum for TPO levels) were obtained by venipuncture into glass tubes containing no additives or anticoagulants. Serum samples were extracted from clotted blood by centrifugation at 400 g for 10 min and stored immediately at −20°C until used.
To study the relationship between endogenous TPO levels and CD34
+ and subset cell yields, samples were drawn prior to each leukapheresis procedure in all 30 patients (101 samples). Further, to determine endogenous TPO response during chemotherapy, serial samples were collected at predetermined intervals. Only the latter 20 of the 30 patients had samples analyzed serially due to the large number of assays performed per patient (60) and the limited availability of the ELISA for TPO. Daily blood samples from those 20 patients were taken prior to starting mobilization chemotherapy on day 1 and continued until platelet counts exceeded 100 × 10 9 /l. In addition, samples were collected starting from the first day of myeloablative chemotherapy (day −8) through PBPCT (day 0) and until platelet counts exceeded 100 × 10 9 /l.
Assay for serum TPO
Endogenous TPO was measured by ELISA as described previously. 30 Briefly, the assay was constructed as a 'sandwich' in which a polyclonal rabbit anti-rHuML was used to capture TPO from the serum. The signal antibody used was a separate polyclonal rabbit anti-rhTPO linked to horseradish peroxidase. Values were read as OD at 450 nm − 650 nm, and TPO levels were determined using a standard curve generated with rhTPO. The limit of detection of the ELISA has been ascertained at 20 pg/ml. Reagents were kind gifts from Amgen, Thousand Oaks, CA, USA.
Immunophenotyping
The appropriate titration of antibodies and isotype control antibodies (IgG 1 , IgG 2a ) was used in all experiments. The monoclonal antibody panel consisted of the following:
/PerCP-anti-HLA-DR (multipotent and differentiated progenitors). All antibodies were purchased from Becton Dickinson, Mountain View, CA, USA.
Staining of each leukapheresis product sample was performed within 2 h of collection. Care was taken to ensure adequate mixing of the leukapheresis product when the samples were obtained. Each sample contained a minimum of 5 × 10 6 leukocytes, was red cell-lysed using FACS Lysing Solution (Becton Dickinson), incubated with the appropriate monoclonal antibodies for 20 min, and washed and resuspended with PBS containing 0.005 m EDTA to prevent platelet adhesion to CD34 + cells. 17 
Flow cytometric analysis
Forward scatter, side scatter, and three-color fluorescence analysis was performed on 101 leukapheresis samples from 30 patients using a FACSort flow cytometer and Cell Quest software (Becton Dickinson). A minimum of 1 × 10 5 CD45 + cells were accepted and stored in list mode. CD34 subset analysis was performed on a minimum of 2500 CD34 + cells using a sequential gating strategy (ISHAGE protocol). 33 Subsets of CD34 + cells were enumerated using three-color fluorescence and multi-gating.
Absolute numbers of CD34 + cells were calculated by multiplication of the total number of nucleated cells by the percentage of CD34 + cells in the leukapheresis product. Since patients had PBPC collections performed to achieve a target value rather than a fixed number of collections, the number of liters of blood processed per leukapheresis varied. It was therefore not possible to use the total number of CD34
+ and subset cells/kg collected as a dependent variable in the analyses of mobilization capability. To correct for this, the total numbers of CD34 + and subset cells/kg were divided by the number of liters of blood processed and the number of leukaphereses to obtain the number of CD34 + cells/kg/l per leukapheresis.
Statistical methods
Statistical analyses were performed using programs of the SAS Institute (SAS Institute, Cary, NC, USA) and the statistical programming language Splus (StatSci, Cambridge, MA, USA Patients had prior exposure to stem cell toxins, if previous chemotherapy regimens before PBPC harvest included BU, BCNU, melphalan, platinum derivatives, procarbazine, nitrogen mustards, or high-dose Ara-C. All statistical tests were carried out at the alpha level of 0.05. Although multiple testing was done no attempt was made to control the overall type I error rate. /l ranged from 6-21 days with a median of 9.5 days. Stable platelet recovery to more than 50 × 10 9 /l ranged from 8-180 days with a median of 13 days.
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Results
Hematopoietic recovery
Twenty
One patient was not included in the analyses due to a failure to achieve the PBPC harvest target. This patient received additional bone marrow (total infusion: 2.5 × 10 6
CD34
+ cells/kg) and recovered ANC to 0.5 × 10 9 /l and 1.0 × 10 9 /l on day 12 and day 14, respectively, but has yet to recover platelet counts to more than 20 × 10 9 /l (day 180+).
Identification of two patient groups based on post-PBPCT platelet recovery
Twenty-nine patients were classified as members of either group I (n = 18; 62%) or group II (n = 11; 38%) based on early platelet recovery to 20 × 10 9 /l and stable platelet recovery to 50 × 10 9 /l. Each criterion alone divided the patients into essentially the same two groups, but to ensure that an early recovery was real, both measures were used to define the groups. Group I patients required 10 or fewer days for early platelet recovery and 14 or fewer days for stable platelet recovery, while group II patients required greater than 10 or 14 days, respectively. More than 70% of group I patients had early platelet recovery within 8 days of reinfusion of autologous PBPCs, contributing to a median platelet recovery 6.5 days shorter than for group II (8 vs 14.5). Similarly, the median stable platelet recovery for group I was 14 days shorter than for group II (11 vs 25).
Patient demographics and treatment characteristics by platelet recovery group
Analysis was performed on essential patient and treatment characteristics to determine if they were associated with early or stable platelet recovery (Tables 1 and 2) . A significant result was that group II appeared to have a much higher proportion of patients previously treated for bone marrow involvement (64% vs 6% for group I, P = 0.001). It is not possible, however, to discern whether the lengthened platelet recovery time post-PBPCT might be due to the previous presence of marrow disease or to its corresponding chemotherapy treatment. While it appears that the groups had a differing pattern of original diagnosis (eg 45% of group II patients had hematological malignancies vs 11% of group I patients), this was not statistically significant. Among the treatment-related variables, the number of supportive platelet transfusions post-PBPCT was significantly greater in group II patients.
Mobilizing capability of CD34 + cells and subsets by group
Analyses to determine whether there were differences in CD34 + cell mobilizing capability showed that the median number of leukaphereses (group I = 2 vs group II = 5, P = 0.04) as well as the median number of days to complete all leukaphereses (group I = 16 vs group II = 25, P = 0.03) were significantly different between the groups. Furthermore, group I patients were able to achieve previously suggested CD34
+ cell/kg target values [11] [12] [13] [14] in fewer leukapheresis procedures (2.5 × 10 6 : group I = 1, group II = 2, P = 0.005; 5.0 × 10 6 : group I = 1, group II = 3, P = 0.01; 10 × 10 6 : group I = 2.5, group II = 5, P = 0.006). Further analysis of mobilization capability showed that (Table 3) .
Number of CD34 + cells and subsets reinfused by group
The median number of CD34 + cells/kg harvested and subsequently reinfused was 2.85 × 10 7 (range: 1.00-7.80 × 10 7 ) for group I and 1.4 × 10 7 (range: 1.00-6.90 × 10 7 ) for group II. Analysis of CD34
+ cell subsets showed that significantly larger numbers of CD34 + /42a + and CD34 + /61 + Mk progenitors were reinfused in group I patients who recovered platelet counts more quickly following myeloablative chemotherapy and transplant (Table 4) . Furthermore, a threshold value of 0.60 × 10 6 CD34 + /61 + and CD34 + /42a + cells/kg was required for rapid platelet recovery (both early and stable). This value separated the majority of group I patients from group II (plots included for early platelet recovery in Figure 1) . Four group II patients, however, received Mk progenitor numbers above the threshold but had delayed early and stable platelet recoveries. 
Serial serum TPO levels and peripheral blood platelet counts
Serial levels of TPO were compared with platelet counts in the peripheral blood for 20 patients undergoing mobilization chemotherapy followed by PBPC harvest, myeloablative chemotherapy, and PBPCT. In all patients, during the course of mobilization and myeloablative chemotherapy, platelet counts dropped significantly and then recovered slowly from the nadir. Endogenous TPO levels, however, followed the opposite trend, rising to an elevated level during platelet nadir and subsequently falling with platelet recovery (Figure 2) . In group II patients, TPO levels remained elevated for the longer duration of thrombocytopenia. Despite the inverse trend observed, there was no statistical correlation between absolute platelet count and serum TPO level after standardizing for wide interpatient variations in TPO levels on specific days.
Serum TPO levels prior to chemotherapy (baseline) and at platelet nadir following mobilization and myeloablative chemotherapy
For the mobilization phase, the mean baseline platelet count was significantly higher in group I patients although the averages for both groups were above the lower normal limit of 150 × 10 9 /l (Table 5) . Mean TPO levels at baseline and platelet nadir were not significantly different between the groups during both phases of treatment. Due to the wide interpatient variation in serum TPO, correlative analyses were performed using the percentage change in TPO levels from baseline to platelet nadir rather than the absolute values. This also eliminated the problem of computing the correlation on non-independent reported measurements. Group I patients had a higher mean percentage change in TPO levels from baseline to platelet nadir during the mobilization chemotherapy regimen.
Correlation between the percentage change in serum TPO levels from baseline to platelet nadir following mobilization chemotherapy and CD34
+ cell and subset leukapheresis yields Examination of plots of serum TPO (prior to the start of each leukapheresis procedure) vs daily CD34
+ cell and subset yields demonstrated no noticeable patterns of association with time. However, a strong correlation was observed between the percentage change in TPO levels and the mean number of CD34 + (r = 0.730, P = 0.002), CD34 
Discussion
This study shows that the number of CD34 + /42a + and CD34
+ cells reinfused is a better predictor of post-transplant platelet recovery than the total dose of CD34 + PBPCs. Patients with delayed platelet recovery do not have a deficiency of circulating endogenous TPO, but their ability to mobilize Mk progenitors is decreased, resulting in smaller numbers of these cells in PBPC autografts. Furthermore, the yields of Mk progenitors correlate with changes in endogenous TPO levels from baseline to the nadir of platelet counts following mobilization chemotherapy.
All patients (with the exception of one who required additional BM support) received twice or more the recommended minimum dose of CD34 + PBPCs for rapid platelet recovery. Nonetheless, an 8-10 day obligatory period of post-transplant thrombocytopenia was observed, similar to other recent studies in which patients also received large numbers of CD34 + PBPCs. [11] [12] [13] [14] Thirty-eight percent of patients did not recover platelet counts within this obligatory period and required significantly more platelet transfusions (group II). This number is in contrast to the 10% reported for patients receiving greater than 5.0 × 10 6 CD34 + cells/kg. 15 However, the lower percentage of patients may be due to the definition of early platelet recovery as р14 days (without reference to platelet transfusions) as opposed to our definition of р10 days. Among the CD34
+ cell sub- 
Table 5
Comparison of mean TPO levels and mean platelet counts at baseline and nadir during mobilization and myeloablative chemotherapy regimens Values reported as mean ± s.e.m. All TPO levels are reported in pg/ml and platelet counts in 10 9 /l. a Percentage change in TPO levels from baseline to platelet nadir following mobilization or myeloablative chemotherapy. b Percentage change in platelet count from baseline to nadir following mobilization or myeloablative chemotherapy.
sets analyzed in the present study, the number of reinfused CD34 + /61 + and CD34 + /42a + cells/kg was the only significant difference between groups I and II. A minimum infusion dose of 0.60 × 10 6 cells/kg was necessary for rapid platelet recovery and is similar to the minimum level of 0.54 × 10 6 cells/kg observed by Dercksen et al. 17 These late Mk precursors usually have a limited capacity for cell division and proliferation and are likely to play a key role in accelerating megakaryocytopoiesis when platelet demand is increased. 24, 31, 32 Analyses of CD34 + cell subsets harvested per kilogram per liter of blood processed revealed that group II patients were relatively poor mobilizers of both differentiated and Mk progenitors. However, since the total number of differentiated progenitors reinfused at transplant was not significantly different between the groups, the ability to mobilize Mk progenitors is of greater clinical importance. Our results indicate that a deficiency of these cells in the PBPC autograft caused by a reduced mobilizing capability contributes to delayed platelet engraftment. The lower numbers of Mk progenitors in PBPC harvests of group II patients may have been due to decreased mar-row stores. A significant factor in the analysis of pretreatment variables was the higher incidence of prior bone marrow disease in group II patients. Although histological examinations revealed normal marrow cellularity in all patients prior to mobilization chemotherapy, group II patients with a history of marrow involvement may have sustained injuries to the stroma. In other group II patients, depletion of the Mk pool may have been a result of increased sensitivity to chemotherapy-induced BM damage. 39 However, not all group II patients had reduced numbers of Mk progenitors in the PBPC autograft. Four patients mobilized and received large numbers of Mk progenitors similar to group I. In these patients, delayed platelet recovery post-PBPCT may have been due to the effects of the myeloablative chemotherapy, qualitative differences in the Mk progenitors reinfused, and/or other factors that inhibit the formation of platelets following reinfusion of Mk progenitors.
Our study shows that changes in endogenous levels of TPO can predict the ability of patients to mobilize CD34 + Mk progenitors. This is consistent with the conclusion of other studies that endogenous TPO levels are reflective of the total Mk rather than platelet mass. [24] [25] [26] [27] [28] Catabolism of TPO is not limited to clearance by the platelet mass, since c-Mpl is also present on the Mk and its progenitors. 24 This may account for the low levels of circulating TPO observed in transcription factor NF-E2 −/− mice, which have a maturation defect with platelet production, 25 and humans with idiopathic thrombocytopenic purpura (ITP), who have increased platelet destruction. 26, 27 Furthermore, no statistical correlation was observed between absolute platelet count and TPO level in the present study after standardizing for interpatient variations in TPO concentrations on specific days. These findings are in agreement with several recent reports. 28, 30 While some studies have shown an apparent correlation between TPO levels and platelet counts, standardization for interpatient variation was not considered since data points from multiple patients were pooled together in a single plot. 27, 40 The importance of measuring the percentage change in TPO and its relationship to Mk mass and progenitor cell yield is illustrated in an idealized model (Figure 3 ). In the group II patient with a lower Mk reserve, there is a smaller percentage decrease from baseline to nadir following mobilization chemotherapy. This is reflected in a smaller increase in TPO level. Consequently, during platelet recovery, the less rapid Mk expansion results in a lower Mk progenitor yield. The model also holds true for the four group II patients in whom percentage changes in TPO and the level of Mk progenitors mobilized were high, similar to group I.
TPO levels remained elevated in group II patients throughout a prolonged period of thrombocytopenia post-PBPCT (median 14 days longer than group I). Delayed platelet engraftment was therefore not due to a deficiency in serum TPO, and this may explain the results of studies of exogenous r-ML administered post-transplant. rhTPO showed no evidence of clinical activity or dose-response on the probability of platelet transfusion independence or number of transfusions with nearly 100-fold increases in serum TPO levels. 41 However, a dose-dependent increase in Figure 3 Idealized model of the relationship between changes in TPO level and Mk mass in a representative group I and group II patient during mobilization chemotherapy. The degree of change in endogenous TPO level and Mk mass is represented by the slopes of the respective lines (plotted on normalized axes). The model depicts TPO level and Mk mass for an individual group I and group II patient to emphasize the importance of comparing percentage changes rather than absolute levels. The squares at PBPC harvest indicate that the group I patient has a more rapid rate of Mk expansion, resulting in a larger Mk progenitor yield.
Mk progenitors was observed with rhTPO as a mobilizing agent, 42 which may benefit group II-type patients. The early identification of patients at risk of delayed platelet engraftment post-PBPCT requires a simple measure of Mk progenitor mobilizing capability. Decreasing percentage changes in TPO during successive cycles of induction chemotherapy may signal a decline in the Mk reserve and the need for alternative transplant strategies. These include early PBPC harvesting, mobilization of PBPCs with r-ML alone or in combination with other cytokines, [42] [43] [44] and ex vivo expansion of Mk progenitors. 18 
